Real-world efficacy and safety of neoadjuvant immunochemotherapy in patients with triple-negative breast cancer.
AIM To evaluate the real‑world efficacy and safety of adding programmed cell death protein 1 (PD-1) inhibitors to neoadjuvant chemotherapy in Chinese patients with triple‑negative breast cancer (TNBC). PATIENTS AND METHODS This single-center retrospective study enrolled 218 TNBC patients receiving neoadjuvant therapy...